How does glp-1 work

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: GLP-1 (glucagon-like peptide-1) is an incretin hormone produced in the intestine that enhances insulin secretion in response to meals, suppresses glucagon release, and slows gastric emptying. It was discovered in the 1980s, with the first GLP-1 receptor agonist, exenatide, approved by the FDA in 2005 for type 2 diabetes. GLP-1 analogs like semaglutide can reduce HbA1c by 1.5-2.0% and promote weight loss of 5-15% of body weight. These drugs work by mimicking natural GLP-1 to regulate blood sugar and appetite.

Key Facts

GLP-1 was discovered in 1983 by scientists studying proglucagon gene expression
GLP-1 receptor agonists can reduce HbA1c levels by 1.0-2.0% in type 2 diabetes patients
Semaglutide (Ozempic, Wegovy) was FDA-approved in 2017 for diabetes and 2021 for obesity
GLP-1 has a very short half-life of 1-2 minutes due to rapid degradation by DPP-4 enzyme
GLP-1 analogs can promote weight loss of 5-15% of body weight over 6-12 months

Overview

GLP-1 (glucagon-like peptide-1) is a 30-amino acid incretin hormone produced primarily by L-cells in the distal ileum and colon in response to nutrient ingestion. Discovered in 1983 during research on the proglucagon gene, GLP-1 emerged as a key regulator of glucose homeostasis. The hormone's therapeutic potential became apparent when researchers found that native GLP-1 could stimulate insulin secretion in a glucose-dependent manner, making it an attractive target for diabetes treatment. However, its extremely short half-life of just 1-2 minutes due to rapid degradation by the DPP-4 enzyme presented a major challenge. This led to the development of GLP-1 receptor agonists with extended half-lives, beginning with exenatide (Byetta) in 2005. Today, GLP-1-based therapies represent a multi-billion dollar market, with drugs like semaglutide (Ozempic, Wegovy) generating over $10 billion in annual sales by 2023.

How It Works

GLP-1 exerts its effects primarily through binding to GLP-1 receptors, which are G-protein coupled receptors expressed in pancreatic beta cells, alpha cells, the brain, heart, and gastrointestinal tract. When GLP-1 binds to receptors on pancreatic beta cells, it activates adenylate cyclase, increasing intracellular cAMP levels, which enhances glucose-dependent insulin secretion. Simultaneously, GLP-1 suppresses glucagon secretion from pancreatic alpha cells, reducing hepatic glucose production. In the gastrointestinal tract, GLP-1 slows gastric emptying and reduces intestinal motility, contributing to increased satiety. In the central nervous system, particularly the hypothalamus, GLP-1 receptor activation promotes feelings of fullness and reduces appetite. The hormone also has cardioprotective effects, improving endothelial function and reducing inflammation. GLP-1 receptor agonists mimic these actions but resist DPP-4 degradation, allowing for once-daily or once-weekly dosing.

Why It Matters

GLP-1-based therapies have revolutionized the management of type 2 diabetes and obesity, two global health crises affecting over 500 million and 1 billion people respectively. Beyond glycemic control, these drugs offer cardiovascular benefits, with some GLP-1 receptor agonists reducing major adverse cardiovascular events by 14-26% in high-risk patients. The weight loss effects have made them valuable tools in obesity treatment, where semaglutide 2.4 mg weekly produces average weight reduction of 15% at 68 weeks. Emerging research suggests potential applications in non-alcoholic steatohepatitis (NASH), Alzheimer's disease, and addiction disorders. However, cost remains a barrier, with prices exceeding $1,000 monthly in the U.S., and side effects like nausea affect 20-50% of users initially.